LaserNCT07351747
Effect of Laser Acupoints on Fallopian Tube Obstruction
A study of Laser and Acupoints, run by Kafrelsheikh University at 1 site in Egypt.
Trial summary
This study aims to determine the efficacy of laser acupoint therapy on treating fallopian tube obstruction. Read more about this study
- Who is it for?
- Ages 20 to 35 years, women only
- Conditions the study is for
- Laser, Acupoints, Fallopian Tube Obstruction
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Apr 2025to 1 Apr 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 35 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Women aged 20-35 years - nulliparous.
- Women diagnosed with fallopian tube obstruction.
- Body mass index less than 30 kg/m2.
- Consent to participate in the study.
- General good health with no major co-existing medical conditions that could interfere with the treatment or outcomes.
- No prior fertility treatments [e.g., In vitro fertilization (IVF), intrauterine insemination (IUI)] within the last 6 months.
- Ability to attend all scheduled sessions and follow-up assessments.
Who cannot join
- Currently pregnant or breastfeeding.
- History of pelvic surgery within the past year.
- Presence of severe systemic diseases such as active cancer or severe cardiovascular diseases.
- History of allergic reactions or adverse responses to acupuncture or laser therapies.
- Currently undergoing hormonal therapy or use of hormonal contraceptives.
- Current or recent history of genital tract infections, including sexually transmitted. infections, which could affect the reproductive system.
- Presence of significant uterine anomalies diagnosed through imaging that could impact fertility.
- Polycystic Ovary Syndrome (PCOS).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Kafrelsheikh University (Faculty of Physical Therapy)
Kafr ash Shaykh, Kafrelsheikh, 33516
Hadeer E Shalaby, MBBCH, 00201554488336, hadeershaalaaby@yahoo.com
Fayiz F Elshamy, MD
About this study
This study aims to determine the efficacy of laser acupoint therapy on treating fallopian tube obstruction.
Read the detailed description
Fallopian tube obstruction is a significant health concern that affects a substantial number of women worldwide, often leading to infertility and other reproductive issues. The fallopian tubes, essential components of the female reproductive system, play a crucial role in the process of conception by facilitating the transport of ova from the ovaries to the uterus.
The laser's focused light energy, when directed at specific acupoints linked to reproductive health, is hypothesized to activate the body's energy pathways or meridians, thereby facilitating healing and restoration of normal tubal function.
Although acupoint therapy shows promise, laser acupoint therapy offers potential advantages over traditional acupuncture by utilizing low-level lasers, which may enhance the treatment's efficacy. Laser acupoint therapy is noninvasive and painless, making it articularly appealing for patients who have a fear of needles or are sensitive to pain.
- Conditions
- Laser, Acupoints, Fallopian Tube Obstruction
- Being tested
- Laser acupoints therapy + Standard care, Standard care
- Medical subject headings
- Fallopian Tube Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Laser acupoints therapy + Standard careOther
Patients will receive laser acupoints therapy addition to standard care.
Standard careOther
Patients will receive placebo laser acupoints therapy in addition to standard care.
| Study group | Role | What they receive |
|---|---|---|
| Study Group (Group A) | Experimental | Patients will receive laser acupoints therapy addition to standard care. Receives: Other: Laser acupoints therapy + Standard care |
| Control Group (Group B) | Placebo comparator | Patients will receive placebo laser acupoints therapy in addition to standard care. Receives: Other: Standard care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tubal patency
Hysterosalpingography (HSG) will be used to assess tubal patency. It is a radiographic technique where a contrast material is injected into the uterine cavity, and X-ray images are taken to evaluate the shape of the uterus and the status of the fallopian tubes. HSG will be applied before the treatment and again three months post-treatment to evaluate changes in tubal patency HSG will be applied before treatment and after 3 months post-treatment.
Measured: 3 months post-treatment
Secondary outcomes (2)
Anti-Müllerian Hormone (AMH) Test
A blood test will be used to measure the level of Anti-Müllerian Hormone (AMH), which is an indicator of the remaining quantity of eggs and ovarian function. This test will be conducted before the treatment and at the third month of treatment to monitor any changes in ovarian reserve.
Measured: 3 months post-treatment
Quantitative Pregnancy Test
A blood test that will be measured the specific level of Human Chorionic Gonadotropin (hCG), which is produced during pregnancy. This test will be performed every month.
Measured: 3 months post-treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2026
- Study start1 Apr 2025
- Primary completion1 Apr 2026 (estimated)
- Study completion1 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LaserStudies of the same condition, open and under way.
- More trials run by Kafrelsheikh UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kafrelsheikh University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hadeer Elsaid Abd-Elsalam Shalaby, Kafrelsheikh University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07351747
- Sponsor's protocol ID
- KFSIRB200-711
- Status last verified
- Jan 2026
- First submitted
- 10 Jan 2026
- Last updated
- 20 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Laser Acupoints on Fallopian Tube Obstruction
- ClinicalTrials.gov ID
- NCT07351747
- Acronym / sponsor ID
- KFSIRB200-711
- Conditions
- Laser, Acupoints, Fallopian Tube Obstruction
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Kafrelsheikh UniversityUniversity, hospital or other
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- 1 Apr 2026 (estimated)
- Study completion
- 1 Apr 2026 (estimated)
- First posted
- 20 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to determine the efficacy of laser acupoint therapy on treating fallopian tube obstruction.
Detailed description
Fallopian tube obstruction is a significant health concern that affects a substantial number of women worldwide, often leading to infertility and other reproductive issues. The fallopian tubes, essential components of the female reproductive system, play a crucial role in the process of conception by facilitating the transport of ova from the ovaries to the uterus.
The laser's focused light energy, when directed at specific acupoints linked to reproductive health, is hypothesized to activate the body's energy pathways or meridians, thereby facilitating healing and restoration of normal tubal function.
Although acupoint therapy shows promise, laser acupoint therapy offers potential advantages over traditional acupuncture by utilizing low-level lasers, which may enhance the treatment's efficacy. Laser acupoint therapy is noninvasive and painless, making it articularly appealing for patients who have a fear of needles or are sensitive to pain.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Study Group (Group A) | Experimental | Other: Laser acupoints therapy + Standard carePatients will receive laser acupoints therapy addition to standard care. |
| Control Group (Group B) | Placebo comparator | Other: Standard carePatients will receive placebo laser acupoints therapy in addition to standard care. |
Who may qualify
- Ages
- 20 to 35 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Women aged 20-35 years - nulliparous.
- Women diagnosed with fallopian tube obstruction.
- Body mass index less than 30 kg/m2.
- Consent to participate in the study.
- General good health with no major co-existing medical conditions that could interfere with the treatment or outcomes.
Key exclusion criteria (8 listed)
- Currently pregnant or breastfeeding.
- History of pelvic surgery within the past year.
- Presence of severe systemic diseases such as active cancer or severe cardiovascular diseases.
- History of allergic reactions or adverse responses to acupuncture or laser therapies.
- Currently undergoing hormonal therapy or use of hormonal contraceptives.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Laser acupoints therapy + Standard carePatients will receive laser acupoints therapy addition to standard care. | Other | Study Group (Group A) |
| Standard carePatients will receive placebo laser acupoints therapy in addition to standard care. | Other | Control Group (Group B) |
Primary outcome
Tubal patency
Time frame: 3 months post-treatment
Hysterosalpingography (HSG) will be used to assess tubal patency. It is a radiographic technique where a contrast material is injected into the uterine cavity, and X-ray images are taken to evaluate the shape of the uterus and the status of the fallopian tubes. HSG will be applied before the treatment and again three months post-treatment to evaluate changes in tubal patency HSG will be applied before treatment and after 3 months post-treatment.
2 secondary outcomes
Anti-Müllerian Hormone (AMH) Test
Time frame: 3 months post-treatment
Quantitative Pregnancy Test
Time frame: 3 months post-treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Laser
Active, not recruiting
A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing
Skin Resurfacing
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
RecruitingPhase 4
Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias
Telangiectasias, Reticular Veins
Not yet recruiting
Recurrent Aphthous Stomatitis Management in Children Using Diode Laser 980 Nanometer Versus Hyaluronic Acid Gel (RCT)
Apthous Ulcer
Not yet recruitingObservational study
Efficacy of Aflibercept (8 mg) With Sequential Laser Photocoagulation for Macular Edema Secondary to Retinal Artery Macroaneurysm: Retrospective Study"
Retinal Arterial Macroaneurysm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of Laser and Acupoints, run by Kafrelsheikh University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hadeer E Shalaby, MBBCH (00201554488336, hadeershaalaaby@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tubal patency (time frame: 3 months post-treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.